A combination of antigenic regions of Toxoplasma gondii microneme proteins induces protective immunity against oral infection with parasite cysts

Journal of Infectious Diseases

Volumn 191, Issue 4, 2005, Pages 637-645

  Beghetto, Elisa ^a   Nielsen, Henrik V ^d   Del Porto, Paola ^a   Buffolano, Wilma ^b   Guglietta, Silvia ^a   Felici, Franco ^a,c   Petersen, Eskild ^e   Gargano, Nicola ^a,f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d STATENS SERUM INSTITUT   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f Kenton Laboratories   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; DNA VACCINE;

ANIMAL CELL; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOGENICITY; MOUTH INFECTION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BRAIN; CELL ADHESION MOLECULES; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; T-LYMPHOCYTES; TOXOPLASMA; TOXOPLASMOSIS; TOXOPLASMOSIS, CONGENITAL; VACCINES, DNA;

EID: 13444305223     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/427660     Document Type: Article

References (51)

1. Beaman MH, McCabe RE, Wong SY, Remington JS. Toxoplasma gondii. In: Mandel GL, Bennett JE, Dolin R, eds. Principles and practices of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:2455-75.
2. Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 1999; 353:1829-33.
3. Remington JS, McLeod R, Desmonts G. Toxoplasmosis. In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant. 5th ed. Philadelphia: WB Saunders, 2000:205-346.
4. Petersen E, Pollak A, Reiter-Owona I. Recent trends in research on congenital toxoplasmosis. Int J Parasitol 2001; 31:115-44.
5. Gilbert R, Dunn D, Wallon M, et al. Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment protocol. Epidemiol Infect 2001; 127:113-20.
6. Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 2004; 113:1567-72.
7. Bertoli F, Espino M, Arosemena JR, Fishback JL, Frenkel JK. A spectrum in the pathology of toxoplasmosis in patients with acquired immunodeficiency syndrome. Arch Pathol Lab Med 1995; 119:214-24.
8. Buxton D. Protozoan infections (Toxoplasma gondii, Neospora caninum and Sarcocystis spp.) in sheep and goats: recent advances. Vet Res 1998; 29:289-310.
9. Buffolano W, Gilbert RE, Holland FJ, Fratta D, Palumbo F, Ades AE. Risk factors for recent Toxoplasma infection in pregnant women in Naples. Epidemiol Infect 1996; 116:347-51.
10. Dubey JP. The scientific basis for prevention of Toxoplasma gondii infection: studies on tissue cyst survival, risk factors, and hygiene measures. In: Ambroise-Thomas P, Petersen E, eds. Congenital toxoplasmosis: scientific background, clinical management and control. Paris: Springer-Verlag, 2000:271-5.
11. Cook AJ, Gilbert RE, Buffolano W, et al. Sources of Toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis. BMJ 2000; 321:142-7.
12. Petersen E, Dubey JP. Biology of Toxoplasma gondii. In: Toxoplasmosis: a comprehensive clinical guide. Joynson DHM, Wreghitt TG, eds. Cambridge: Cambridge University Press, 2001.
13. Denkers EY. T lymphocyte-dependent effector mechanisms of immunity to Toxoplasma gondii. Microbes Infect 1999; 1:699-708.
14. Denkers EY, Gazzinelli RT. Regulation and function of T-cell mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev 1998; 11:569-88.
15. Yap GS, Sher A. Cell-mediated immunity to Toxoplasma gondii: initiation, regulation and effector function. Immunobiology 1999; 201:240-7.
16. Kang H, Remington JS, Suzuki Y. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-γ, TNF-α, and inducible nitric oxide synthase. J Immunol 2000; 164:2629-34.
17. Sayles PC, Gibson GW, Johnson LL. B cells are essential for vaccination induced resistance to virulent Toxoplasma. Infect Immun 2000; 68:1026-33.
18. Soldati D, Dubremetz JF, Lebrun M. Microneme proteins: structural and functional requirements to promote adhesion and invasion by the apicomplexan parasite Toxoplasma gondii. Int J Parasitol 2001; 31:1293-302.
19. Tomley FM, Soldati DS. Mix and match modules: structure and function of microneme proteins in apicomplexan parasites. Trends Parasitol 2001; 17:81-8.
20. Beghetto E, Spadoni A, Buffolano W, et al. Molecular dissection of the human B-cell response against Toxoplasma gondii infection by lambda display of cDNA libraries. Int J Parasitol 2003; 33:163-73.
21. Lourenco EV, Pereira SR, Faca VM, et al. Toxoplasma gondii micronemal protein MIC1 is a lactose-binding lectin. Glycobiology 2001; 11:541-7.
22. Wan KL, Carruthers VB, Sibley LD, Ajioka JW. Molecular characterisation of an expressed sequence tag locus of Toxoplasma gondii encoding the micronemal protein MIC2. Mol Biochem Parasitol 1997; 84:203-14.
23. Rabenau KE, Sohrabi A, Tripathy A, et al. TgM2AP participates in Toxoplasma gondii invasion of host cells and is tightly associated with the adhesive protein TgMIC2. Mol Microbiol 2001; 41:537-47.
24. Brecht S, Carruthers VB, Ferguson DJ, et al. The Toxoplasma micronemal protein MIC4 is an adhesin composed of six conserved apple domains. J Biol Chem 2001; 276:4119-27.
25. Reiss M, Viebig N, Brecht S, et al. Identification and characterization of an escorter for two secretory adhesins in Toxoplasma gondii. J Cell Biol 2001; 152:563-78.
26. Meissner M, Reiss M, Viebig N, et al. A family of transmembrane microneme proteins of Toxoplasma gondii contain EGF-like domains and function as escorters. J Cell Sci 2002; 115:563-74.
27. Hoff EF, Cook SH, Sherman GD, et al. Toxoplasma gondii: molecular cloning and characterization of a novel 18-kDa secretory antigen, TgMIC10. Exp Parasitol 2001; 97:77-88.
28. Donahue CG, Carruthers VB, Gilk SD, Ward GE. The Toxoplasma homolog of Plasmodium apical membrane antigen-1 (AMA-1) is a microneme protein secreted in response to elevated intracellular calcium levels. Mol Biochem Parasitol 2000; 111:15-30.
29. Beghetto E, Pucci A, Minenkova O, et al. Identification of a human immunodominant B-cell epitope within the GRA1 antigen of Toxoplasma gondii by phage display of cDNA libraries. Int J Parasitol 2001; 31:1659-68.
30. Minenkova O, Pucci A, Pavoni E, et al. Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. Int J Cancer 2003; 106:534-44.
31. Sambrook J, Russell DW. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2001.
32. Jensen L, Petersen E, Henriksen SA, Dietz HH, Lindt P. Monoclonal antibodies to Toxoplasma gondii strain 119 identify recently isolated Danish strains in one group. Int J Parasitol 1998; 28:1305-13.
33. Di Cristina M, Del Porto P, Buffolano W, et al. The Toxoplasma gondii bradyzoite antigens BAG1 and MAG1 induce early humoral and cell-mediated immune responses upon human infection. Microbes Infect 2004; 6:164-71.
34. Fourmaux MN, Achbarou A, Mercereau-Puijalon O, et al. The MIC1 microneme protein of Toxoplasma gondii contains a duplicated receptor-like domain and binds to host cell surface. Mol Biochem Parasitol 1996; 83:201-10.
35. + cytotoxic T lymphocytes specific for Toxoplasma gondii lyse tachyzoite-infected target cells. J Immunol 1993; 151:2024-31.
36. Daubener W, Mackenzie C, Hadding U. Establishment of T-helper type 1 and T-helper type 2-like human Toxoplasma antigen-specific T cell clones. Immunology 1995; 86:79-85.
37. + T cell clones from healthy, latently infected humans display a Th0 profile of cytokine secretion. Eur J Immunol 1995; 25:1298-305.
38. Pistoia V, Facchetti P, Ghiotto F, Cesbron-Delauw MF, Prigione I. Characterization of human T cell clones specific for Toxoplasma gondii. Curr Top Microbiol Immunol 1996; 219:165-73.
39. Purner MB, Berens RL, Nash PB, et al. CD4-mediated and CD8-mediated cytotoxic and proliferative immune responses to Toxoplasma gondii in seropositive humans. Infect Immun 1996; 64:4330-8.
40. Prigione I, Facchetti P, Lecordier L, et al. T cell clones raised from chronically infected healthy humans by stimulation with Toxoplasma gondii excretory-secretory antigens cross-react with live tachyzoites: characterization of the fine antigenic specificity of the clones and implications for vaccine development. J Immunol 2000; 164:3741-8.
41. Fatoohi AF, Cozon GJ, Greenland T, et al. Cellular immune responses to recombinant antigens in pregnant women chronically infected with Toxoplasma. Clin Diagn Lab Immunol 2002; 9:704-7.
42. Alarcon JB, Waine GW, McManus DP. DNA vaccines: technology and application as anti-parasite and anti-microbial agents. Adv Parasitol 1999; 42:343-410.
43. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 1988; 240:516-8.
44. Nielsen HV, Lauemoller SL, Christiansen L, Buus S, Fomsgaard A, Petersen E. Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene. Infect Immun 1999; 67:6358-63.
45. Angus CW, Klivington-Evans D, Dubey JP, Kovacs JA. Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. J Infect Dis 2000; 181:317-24.
46. Vercammen M, Scorza T, Huygen K, et al. DNA vaccination with genes encoding Toxoplasma gondii antigens GRA1, GRA7, and ROP2 induces partially protective immunity against lethal challenge in mice. Infect Immun 2000; 68:38-45.
47. Desolme B, Mevelec MN, Buzoni-Gatel D, Bout D. Induction of protective immunity against toxoplasmosis in mice by DNA immunization with a plasmid encoding Toxoplasma gondii GRA4 gene. Vaccine 2000; 18:2512-21.
48. Chen G, Guo H, Lu F, Zheng H. Construction of a recombinant plasmid harbouring the rhoptry protein 1 gene of Toxoplasma gondii and preliminary observations on DNA immunity. Chin Med J 2001; 114:837-40.
49. Leyva R, Herion P, Saavedra R. Genetic immunization with plasmid DNA coding for the ROP2 protein of Toxoplasma gondi. Parasitol Res 2001; 87:70-9.
50. Ismael AB, Sekkai D, Collin C, Bout D, Mevelec MN. The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis. Infect Immun 2003; 71:6222-8.
51. Jones T, Stern A, Lin R. Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant. Eur J Clin Microbiol Infect Dis 1994; 13(Suppl 2):S47-53.